Managing type 2 diabetes often involves complex medication regimens, but potassium imbalance, especially hyperkalemia, can be a life-threatening side effect. This study sheds light on the impact of different diabetes medications, particularly SGLT-2 inhibitors and GLP-1 receptor agonists, on the risk of hyperkalemia in real-world clinical settings.
The researchers analyzed data from three large U.S. healthcare databases. The study included patients with type 2 diabetes who were treated with either SGLT-2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors, over several years. The study’s primary objective was to compare the risk of hyperkalemia—a condition in which potassium levels in the blood rise to dangerous levels—across these medication classes.
“We observed a significant reduction in the risk of hyperkalemia among patients treated with SGLT-2 inhibitors and GLP-1 receptor agonists compared to those using DPP-4 inhibitors,” says Dr. Bykov, one of the lead researchers. “This finding is particularly relevant as hyperkalemia can lead to serious complications, including cardiac arrest, in patients with diabetes.”
Comparing Medications for Safer Outcomes
One of the study’s notable strengths is the comparison between these commonly prescribed diabetes medications. The results indicate that both SGLT-2 inhibitors and GLP-1 receptor agonists offer a safer profile in terms of potassium balance, particularly in contrast to DPP-4 inhibitors. Hyperkalemia, while often overlooked, poses a significant threat to patients with type 2 diabetes, especially those with comorbidities like chronic kidney disease.
“Given the frequent use of these medications in clinical practice, it’s crucial for healthcare providers to be aware of their differential impacts on potassium levels,” adds Dr. Paik, a senior contributor to the study. “Our findings support a shift toward prescribing SGLT-2 inhibitors or GLP-1 receptor agonists for patients at risk of potassium imbalance.”
Real-World Impact of SGLT-2 and GLP-1 Drugs
The real-world data analyzed in this study presents compelling evidence supporting the use of SGLT-2 and GLP-1 drugs in managing potassium levels. Importantly, these drugs have already demonstrated benefits for blood sugar control and cardiovascular health, and now they show promise in preventing hyperkalemia.
“This research not only broadens our understanding of diabetes management but also underscores the importance of personalized treatment strategies,” says Dr. Wexler, another co-author. “It’s about giving patients the right treatment, considering not just their diabetes, but other risk factors like potassium imbalance.”
The study’s findings could influence clinical guidelines and provide clinicians with new strategies to reduce adverse outcomes related to hyperkalemia. As the prevalence of type 2 diabetes continues to rise, these insights may help to better manage the condition and improve patient safety.
Implications for Future Diabetes Treatment
Moving forward, this research opens the door for further studies examining how different diabetes medications affect potassium levels and other electrolytes. Future investigations could also look into the long-term outcomes of using SGLT-2 inhibitors and GLP-1 receptor agonists in diverse populations, especially those at higher risk of electrolyte imbalances.
“These findings could shape the future of diabetes care, particularly for patients vulnerable to hyperkalemia,” concludes Dr. Patorno. “It’s about improving the safety of treatments and reducing the risks associated with managing diabetes.”
Citation:
Bykov K, Cromer SJ, Fu EL, Paik JM, Patorno E, Wexler DJ. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population-based cohort study. BMJ. 2024;385. doi:10.1136/bmj-2023-078483.
License:
This content is generated from the original article and it’s under Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.